Anti-EGFRvIII chimeric antigen receptor transduced T-cells - Kite PharmaAlternative Names: Anti-EGFRvIII CAR; EFGRvIII CAR
Latest Information Update: 11 Jan 2016
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class CAR-T cell therapies
- Mechanism of Action Epidermal growth factor receptor antagonists; Gene transference; T lymphocyte replacements; T-cell receptor antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma
Most Recent Events
- 17 Sep 2015 Phase I/II development is ongoing in USA